Artwork

Content provided by Informa TechTarget. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Informa TechTarget or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Exploring gaps in GLP-1 research, care, and coverage

16:35
 
Share
 

Manage episode 449532754 series 2797294
Content provided by Informa TechTarget. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Informa TechTarget or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.

Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.

In today’s episode, we’ll cover

  • The significant progress made in GLP-1 research, care delivery, and insurance coverage
  • Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
  • Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management

And more!

To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies

Resources:

  continue reading

121 episodes

Artwork
iconShare
 
Manage episode 449532754 series 2797294
Content provided by Informa TechTarget. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Informa TechTarget or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.

Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.

In today’s episode, we’ll cover

  • The significant progress made in GLP-1 research, care delivery, and insurance coverage
  • Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
  • Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management

And more!

To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies

Resources:

  continue reading

121 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play